臨床研究等提出・公開システム

Date of registration	Dec. 16, 2014
Last modified on	Dec. 17, 2018
Trial ID	jRCT2080222696

Scientific Title	A phase III long-term study of HP-3000 in patients with Parkinson's disease
Public Title	Long-term study of HP-3000 in patients with Parkinson's disease

Completion Date or Terminated date
Actual Enrolled Number
Baseline Characteristics
Participant flow
Adverse events
Primary Outcome Measures
Secondary Outcome Measures
Brief summary
Posting of journal publication
Date of the first journal publication of results
URL hyperlink(s) related to results and publications

Plan to share IPD
Plan description
URL link to protocol file(s)
Version of protocol file(s)	version: date:

Contact for Scientific Queries	Name
	Contact Name for Scientific Queries
	Address
	Phone Number
	E-mail Address

Contact for Public Queries	Name
	Contact Name for Public Queries	Hisamitsu Pharmaceutical Co., Inc.
	Address	sodanshitsu@hisamitsu.co.jp
	Phone Number
	E-mail Address

Recruitment Status

Date of First Enrolment
Target Sample Size
Study Type		Interventional
Study Design	Study Design	Multicenter, open-label, single group assignment
Study Design	Objective
Phase		3
Key inclusion & exclusion criteria	Inclusion Criteria	Patients diagnosed with Parkinson's disease in stages 1 to 4 on the modified Hoehn & Yahr scale.
	Exclusion Criteria	- Patients with history of hypersensitivity to ropinirole. - Patients with severe hepatic dysfunction. - Patients who have cutaneous abnormality at planned application site that can be worsen by application with investigational product.
	Minimum Age	20age old over
	Maximum Age	79age old under
	Gender	Both
Health Condition or Problem Studied		Parkinson's disease
Intervention(s)		investigational material(s) Generic name etc : HP-3000(ropinirole hydrochloride patch) INN of investigational material : Therapeutic category code : 116 Antiperkinsonism agents Dosage and Administration for Investigational material : Transdermal, once daily
Health Condition(s) Keyword
Intervention(s) Keyword
Health Condition(s) Code
Intervention(s) Code
Primary Outcome		Safety, and efficacy.
Secondary Outcome

Primary Sponsor	Hisamitsu Pharmaceutical Co.,Inc.
Secondary Sponsor

Name of Funding Organization
Name of Research Funding

Name of IRB
Address of IRB
Phone Number of IRB
E-mail Address of IRB
Status of IRB Review
Date of Approval by IRB

Secondary ID No.	JapicCTI-142748
Name of Other Registries

Countries / Regions of Recruitment

History of Changes

No	Publication date
5	Dec. 17, 2018	(this page)	Changes
4	Nov. 16, 2017	Detail	Changes
3	Nov. 16, 2017	Detail	Changes
2	Dec. 16, 2014	Detail	Changes
1	Dec. 16, 2014	Detail

List of change history